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Abstract
Objective—To analyze reasons for low enrollment in an RCT of the effect of hydrocortisone for 
cardiovascular insufficiency on survival without neurodevelopmental impairment (NDI) in term/
late-preterm newborns.
Study Design—The original study was a multicenter RCT. Eligibility: ≥34 weeks’ gestation, 
<72° old, mechanically ventilated, receiving inotrope. Primary outcome was NDI at 2 years; 
infants with diagnoses at high risk for NDI were excluded. This paper presents an analysis of 
reasons for low patient enrollment.
Result—257 of 932 otherwise eligible infants received inotropes; however, 207(81%) had 
exclusionary diagnoses. Only 12 infants were randomized over 10 months; therefore, the study 
was terminated. Contributing factors included few eligible infants after exclusions, open-label 
steroid therapy, and a narrow enrollment window.
Conclusion—Despite an observational study to estimate the population, very few infants were 
enrolled. Successful RCTs of emergent therapy may require fewer exclusions, a short-term 
primary outcome, waiver of consent, and/or other alternatives.
Clinical trial registration—Clinicaltrials.gov, NCT01954056
Introduction
Cardiovascular insufficiency, defined as inadequate blood flow to meet metabolic needs, 
frequently complicates hypoxic respiratory failure in critically ill term and late preterm 
newborns admitted to newborn intensive care units (NICUs)1. Critically ill term and late 
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preterm infants presenting with low blood pressure, prolonged capillary filling time, low 
urine output, and/or metabolic acidosis, frequently receive fluid boluses, inotropic drugs, 
and, with increasing frequency, hydrocortisone to improve systemic blood flow1,2. One large 
observational study reported that 21% of all mechanically ventilated infants born at ≥34 
weeks gestation were treated with an inotrope, and 41% of those treated with an inotrope 
were also treated with hydrocortisone2. Although some of these therapies have been tested in 
extremely preterm infants, no randomized controlled trials (RCTs) have tested the effects of 
any of these therapies on short or long-term outcomes in the critically ill term and late 
preterm population. Small studies in these infants have reported that many infants with 
cardiovascular dysfunction have low cortisol concentrations3–7. Case series and retrospective 
studies have also demonstrated improved cardiovascular stability following hydrocortisone 
treatment7–9; however, no RCT has evaluated the effects of hydrocortisone on cardiovascular 
function, short-term in-hospital outcomes, or long-term neurodevelopment in term and late 
preterm infants.
To design a randomized trial of hydrocortisone for cardiovascular insufficiency in this 
population, we first performed an observational study to document: (1) the relationship of 
blood pressure to the receipt of treatment for cardiovascular insufficiency; (2) the utility of 
four specific definitions of cardiovascular insufficiency to predict short-term outcomes; and 
(3) the availability of sufficient numbers of infants for the planned study.1,2 We found little 
correlation between blood pressure values and treatments administered; however, infants 
receiving inotropic therapy had significantly higher incidence of many short-term adverse 
outcomes, including mortality1, 2. Therefore, we chose receipt of inotropic therapy as a 
reasonable and clear criterion for study entry, and undertook a multicenter RCT to determine 
the short- and long-term effects of hydrocortisone treatment for cardiovascular insufficiency 
in critically ill term and late preterm infants in the Eunice Kennedy Shriver National Institute 
for Child Health and Human Development (NICHD) Neonatal Research Network (NRN). 
Because death or neurodevelopmental impairment (NDI) at 2 years was considered a much 
more important outcome than a short-term measure (e.g., length of inotropic therapy), we 
chose this as the primary study outcome.
During the study enrollment period (August 2014 – July 2015), all infants admitted to 
participating centers were screened for eligibility. Of 932 who met initial eligibility criteria 
(Figure: ≥34 weeks of gestation, intubated and mechanically ventilated), 257 (28%) received 
inotropic support. However, 207 (81%) were excluded for one or more of the pre-specified 
criteria (Table 1), and only 12 infants were enrolled. For that reason, the NRN Steering 
Committee voted to terminate the study on July 28, 2015, due to the inability to enroll the 
planned sample size in a reasonable period. This paper presents the results of our analysis of 
barriers to enrollment in the RCT.
Methods
(1) RCT study design
The original study was a randomized, multicenter, double-masked, placebo-controlled trial 
conducted at 16 centers of the Eunice Kennedy Shriver National Institute of Child Health 
and Human Development’s Neonatal Research Network (NRN) centers. Institutional review 
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boards at all study sites approved the study and eligible patients were enrolled after parental 
consent. All infants admitted to the newborn intensive care unit(s) at the study sites were 
screened for eligibility. Infants were eligible if they were ≥34 weeks’ gestation, admitted to a 
study site before 48 hours’ postnatal age, intubated and mechanically ventilated for at least 2 
hours in the first 72 postnatal hours, and met the study definition of cardiovascular 
insufficiency: receipt of dopamine or dobutamine at ≥5 mcg/kg/minute or epinephrine or 
norepinephrine at ≥0.01 mcg/kg/min. The primary study outcome was death or 
neurodevelopmental impairment (NDI) at 22 – 26 months. Exclusions to study are shown in 
Table 1, and included diagnoses that placed infants at high risk of neurodevelopmental 
impairment, as well as open-label glucocorticoid treatment. Randomization was stratified by 
Network center using a randomly permuted block algorithm through a centralized web-
based process. A sample size of 646 infants was chosen to detect a difference of 10 
percentage points in the primary outcome, with 80% power.
Procedures
Based on limited pharmacokinetic and clinical effect data10, hydrocortisone was given as a 1 
mg/kg loading dose followed by 0.5 mg/kg q 6 hours x 12 doses, 0.5 mg/kg q 12 hours x 4 
doses and 0.5 mg/kg q day x 1 dose, for a total treatment course of 7 days. Placebo was an 
equal volume of normal saline. One blood sample (1 ml) was obtained for cortisol assay ≤4 
hours before starting study drug from each enrolled patient whose parent gave consent. All 
samples were analyzed by one laboratory (University of New Mexico Clinical and 
Translational Science Center Core Laboratory). Indomethacin and ibuprofen were not 
permitted during the study drug treatment period because of the potential interaction of non-
steroidal anti-inflammatory agents with glucocorticoids11.
(2) Analysis of barriers to study entry
As study enrollment proceeded and far fewer infants were enrolled than anticipated, detailed 
delineations of reasons for non-enrollment were acquired from each center and evaluated. 
These reasons appeared to stem primarily from factors that could not be changed within the 
study protocol; therefore, patient enrollment was terminated. This report presents the results 
of the investigation into the reasons for lack of enrollment.
Results
The first centers began screening in August of 2014 and by July 2015, all 16 study centers 
were screening. At that time, seven sites had been screening for >6 months. During the 
patient screening period, 932 infants were admitted to the study centers and met the 
screening entry criteria of being ≥34 weeks of gestation, intubated and mechanically 
ventilated, and admitted to an enrolling NRN center at <48 hours postnatal age (Figure). Of 
these, 257 (28%) infants were receiving ≥5 mcg/kg/minute of dopamine or equivalent 
inotrope dose, similar to the percentage in the observational study2. Of these infants, 
however, 207 (81%) were excluded for one or more of the pre-specified criteria (Table 1, 
Figure), leaving 50 infants eligible. The parents of 21 of these infants were approached for 
consent, and 12 (57%) consented to the study. Reasons that 29 families were not approached 
for consent are detailed in the Figure. In view of continuing low enrollment (3 infants in the 
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final 3 months), enrollment was suspended on July 23, 2015. The NRN Steering Committee 
voted to terminate the study on July 28, 2015, due to the inability to enroll the planned 
sample size in a reasonable period.
Of the 12 enrolled infants, four were late preterm and eight were term. Median age at study 
enrollment was 37 hours, with a range of 2 to 46 hours. Primary diagnoses for the 12 
enrolled patients are shown in Table 2, and are compared with the distribution of those 
diagnoses in the previous observational study. Eight infants (67%) had blood drawn for pre-
treatment cortisol concentration, and values were 10.8 [6.1 – 16.3], 2.0 – 222 mcg/dL 
(median [25 – 75%ile], range).
Discussion
Critically ill term and late preterm infants are frequently exposed to therapies intended to 
treat cardiovascular insufficiency, including fluid boluses, inotropes and, increasingly, 
hydrocortisone1,2. Unfortunately, none of these therapies has been subjected to a large 
randomized controlled trial of short- and long-term outcomes in the term and late preterm 
population. The objective of this RCT was to evaluate the efficacy and safety of 
hydrocortisone treatment for cardiovascular insufficiency in a large, multicenter RCT of 
critically ill, mechanically ventilated term and late preterm infants; however, we failed to 
achieve that objective due to low patient enrollment. We therefore sought to characterize the 
reasons for low enrollment in this study, to aid in planning future studies in critically ill 
newborn infants.
We found three specific factors to be important contributors to low enrollment. First, 
although a reasonable number of potentially eligible patients were admitted, the choice of 
neurodevelopmental impairment (NDI) as the primary outcome measure, and the 
accompanying exclusion of infants at high risk for NDI, resulted in the loss of the majority 
of otherwise eligible patients (193 of 257, Table 1). The most frequent diagnoses resulting in 
exclusion for this reason were hypoxic-ischemic encephalopathy (HIE), congenital anomaly, 
congenital heart disease, and CNS or chromosomal abnormality. Death or NDI was chosen 
as the primary outcome because it was thought to be much more significant than a short-
term benefit such as decreased time on inotropic support12. Unfortunately, the choice to 
exclude groups of infants at high risk for abnormal neurodevelopmental outcomes was the 
major contributor to the failure of the study. We can speculate that if these patients had been 
included in the study and balanced in the randomization, valuable information about the 
efficacy of hydrocortisone therapy in these high-risk groups would have resulted. However, 
it is also possible that the variable effects of the different diagnoses or an unbalanced 
randomization would have hopelessly confounded the interpretation of the study results. 
From our results, it would appear that designation of a short-term measure as the primary 
outcome, including groups at high risk for neurodevelopmental difficulties, would be the 
only way to achieve adequate patient enrollment. Neurodevelopmental outcomes at age two 
would then be a secondary outcome.
The second major barrier to enrollment was the use of open-label glucocorticoid prior to 
study entry in 72 (28%) of the infants. While 39 of these infants had an additional reason for 
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exclusion, steroids alone were the reason for exclusion of 33 infants, 13% of the potentially 
eligible population. In the observational study, the median time of the first glucocorticoid 
dose was 25 hours for term and 33 hours for late preterm infants, and it was hoped that these 
infants could be enrolled in the RCT before steroids had been administered. However, the 
median age at randomization into the RCT was 37 hours, and 72 infants had received open-
label glucocorticoid treatment prior to randomization. Only 4 patients were excluded due to 
physician refusal, suggesting that lack of physician equipoise was not a major issue; 
however, the number of infants receiving glucocorticoids before the median enrollment age 
of 37 hours suggests a clinical bias in favor of hydrocortisone treatment. Faced with a 
critically ill patient with evidence of cardiovascular insufficiency, clinicians may reasonably 
feel an urgency to treat quickly, with multiple therapeutic agents if necessary, to raise the 
blood pressure and improve the circulation. This leaves the research team with a very narrow 
window for approaching the family for consent and obtaining the study drug from the 
investigational pharmacy. In some cases, families were not approached for consent for this 
reason.
The third major barrier to enrollment was difficulty in obtaining consent and randomizing 
infants in the narrow enrollment window, leading to a lower than expected enrollment rate 
(24%). The consent rate for families who were approached for consent was similar to other 
interventional studies of medications in common use in the NICU, at 57% (12 of 21)13. 
However, consent was not requested in 29 other cases. Some parents were not available; 
however, for many others, despite 24/7 screening, the process of participant identification, 
parental consent, and randomization proved too time-consuming to enable patients to be 
enrolled in the study prior to open-label glucocorticoid therapy. Alternative approaches to 
obtaining consent, such as approaching parents when their infants are first admitted and 
preparing study drug at that time, might increase enrollment. However, as only 28% of the 
initially eligible population ever received inotropic support, this method would greatly 
increase the amount of time and resources required for each patient enrolled.
In addition to specific barriers to enrollment in this study, we also noted a decline in the 
number of eligible infants. Based on the observational study, we anticipated an eligible 
population of >125/year, even after allowing for the specified exclusions. The decreased 
number of eligible infants we encountered between 2009 and 2015 is consistent with clinical 
perceptions and with other studies documenting that fewer term and late preterm infants are 
being intubated and mechanically ventilated in recent years14–17.
In summary, enrollment in this study was handicapped by a number of factors. First, the 
choice of long-term neurodevelopment rather than short-term cardiovascular effects as the 
primary study outcome resulted in the exclusion of the preponderance of otherwise eligible 
patients. Second, the process of obtaining informed consent from overwhelmed families just 
after the birth of an unexpectedly critically ill infant is delicate, difficult, and time 
consuming, resulting in a detrimental delay in study entry, with exclusion of additional 
infants due to intervening glucocorticoid exposure. The combination of these challenging 
factors made the timely and successful completion of this study impossible. Although 
determining the effect of therapies for cardiovascular insufficiency on survival without 
neurodevelopmental impairment may well be more important than short-term effects, this 
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was not feasible as a primary outcome in our study. In retrospect, it may have been more 
practical to choose a short-term primary outcome (e.g., days on inotropic therapy), with 
long-term neurodevelopment as a secondary outcome, resulting in a much larger population 
of eligible infants. In addition, as others have noted, fewer term and late preterm infants are 
presenting over time with diagnoses such as those in Table 2.
Critically ill term and late preterm infants remain a population at high risk for clinically 
important adverse outcomes as well as for adverse consequences from the use of off-label, 
unproven therapies. None of the therapies commonly used to treat cardiovascular 
insufficiency in term or late-preterm newborn infants has been subjected to a rigorous 
randomized controlled trial that includes monitoring of long-term outcomes, yet most such 
infants are exposed to one or more of these therapies1,2. Barriers to successfully performing 
rigorous clinical studies foster the adoption of unproven therapies, which in turn make such 
studies more difficult to perform. Alterations in study design, such as (1) accepting short-
term effects on cardiovascular function as a primary outcome in order to include more 
patients; (2) obtaining a waiver of consent from institutional review boards to enable more 
expeditious enrollment and drug initiation for therapies in common use in the NICU; (3) 
utilizing the clinical pharmacy to prepare study drugs that are in current use for more timely 
delivery to the bedside; or other alternatives, will be necessary to achieve the vital goal of 
understanding the effects of therapeutic interventions in this critically ill population.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Consort flow diagram
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Table 1
Infants excluded from the RCT
Met exclusion criteriona
Total excluded: 882 of 932
Percentage of all screened 
infants (N=932)
N (%)
Of infants on inotrope therapy 
meeting study entry criteria 
(N=257)
N (%)
Major anomaly (including diaphragmatic hernia) 228 (24.5%) 75 (29.2%)
Prior dexamethasone or hydrocortisone 79 (8.5%) 72 (28%) b
Therapeutic hypothermia for HIE 146 (15.7%) 58 (22.6%)
Congenital heart disease 108 (11.6%) 35 (13.6%)
ECMO 28 (3.0%) 22 (8.6%)
Structural CNS abnormality 30 (3.2%) 14 (5.4%)
Limited treatment for poor prognosis 29 (3.1%) 13 (5.1%)
Chromosomal disorder 37 (4.0%) 11 (4.3%)
Intubated for surgery or airway anomaly 73 (7.8%) 5 (1.9%)
Ibuprofen or indomethacin <24hrs prior 2 (0.2%) 1 (0.4%)
Hypotension due to treatable cause (e.g., hemorrhage or pneumothorax) 6 (0.6%) 3 (1.2%)
Hypertension > 95th percentile 9 (1.0%) 1 (0.4%)
Pituitary hypoplasia or congenital adrenal hyperplasia 1 (0.1%) 0 (0.0%)
aAn infant may have met more than one exclusion criterion
bOnly 33 of these were excluded for the sole reason of prior dexamethasone or hydrocortisone therapy.
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Table 2
Comparison of primary clinical diagnoses in the observational study and the RCTa
Observational study RCT
Respiratory distress syndrome 68% 8 (75%)
Pneumothorax/mediastinum 15% 2 (17%)
Meconium aspiration syndrome 14% 7 (58%)
Pneumonia 10% 1 (8%)
Necrotizing enterocolitis 0 1 (8%)
Persistent pulmonary hypertension 19% 5 (42%)b
aAn infant may have multiple diagnoses
bAll infants with persistent pulmonary hypertension also had one or more of the other diagnoses in the Table
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